The Experts below are selected from a list of 384 Experts worldwide ranked by ideXlab platform
Tamotsu Matsuda - One of the best experts on this subject based on the ideXlab platform.
-
effect of inhaled Procaterol on cough receptor sensitivity to capsaicin in patients with asthma or chronic bronchitis and in normal subjects
Thorax, 1993Co-Authors: Masaki Fujimura, Sayuri Sakamoto, Yumie Kamio, T Bando, K Kurashima, Tamotsu MatsudaAbstract:BACKGROUND--To evaluate the effect of inhaled beta 2 adrenergic agonists on the sensitivity of airway cough receptors, the effect of inhaled Procaterol on cough induced by aerosolised capsaicin, a stimulant of C fibres, was studied in patients with asthma or chronic bronchitis and in normal subjects. METHOD--Eleven patients with asthma and 10 with chronic bronchitis and 14 normal subjects participated. Increasing concentrations of capsaicin solution were inhaled for 15 seconds by tidal breathing through the mouth at one minute intervals until five or more coughs were elicited, before and 30 minutes after inhalation of 20 micrograms Procaterol or placebo (freon gas alone) through a metered dose inhaler. Cough threshold was defined as the lowest concentration of capsaicin that elicited five or more coughs. To evaluate the bronchodilator effect of Procaterol and the bronchoconstrictor effect of inhaled capsaicin, forced expiratory volume in one second (FEV1) was measured before and one minute after a capsaicin provocation test. This test was carried out both before and 30 minutes after treatment with Procaterol or placebo. RESULTS--The geometric mean value of cough threshold to capsaicin was significantly increased by Procaterol and placebo in both groups of patients but not in the control subjects. The increment in the cough threshold was not significantly different between the treatments with Procaterol and placebo in each group. FEV1 was significantly increased by Procaterol but not by placebo in all three groups. CONCLUSIONS--Inhaled Procaterol has no effect on airway cough receptor sensitivity to capsaicin. The attenuation of the cough sensitivity seen after inhalation of Procaterol in patients with asthma and bronchitis may result from tachyphylaxis to capsaicin.
-
inhibitory effect of inhaled Procaterol on anaphylactic bronchoconstriction and thromboxane a2 production in guinea pigs
Clinical & Experimental Allergy, 1991Co-Authors: Masaki Fujimura, Sayuri Sakamoto, Kouichi Nishi, Motoyasu Saito, Yasushi Miyake, Tamotsu MatsudaAbstract:Summary This study was designed to examine whether an inhaled β2-agonist, Procaterol, inhibits thromboxane A2 (TXA2) production induced by antigen challenge in passively sensitized guinea-pigs in vivo. Antigen-induced bronchoconstriction was markedly inhibited by pre-treatment with Procaterol. Inhaled Procaterol significantly reduced in a dose-dependent manner the increment in TXB2 concentration in bronchoalveolar lavage fluid obtained 5 min after antigen challenge. Aerosol administration of Procaterol significantly inhibited bronchoconstriction induced by inhaled hislainine. These results suggest that inhalation of procalerol has an inhibitory effect on antigen-induced TXA2 production as well as a protective effect against bronchoconstriction induced by bronchoactive agents.
Ammarin Thakkinstian - One of the best experts on this subject based on the ideXlab platform.
-
effects of oral Procaterol for postinfectious cough in adults single centre randomized double blind placebo controlled trial
Korean Journal of Family Medicine, 2021Co-Authors: Prapaporn Pornsuriyasak, Sasivimol Rattanasiri, Nattawut Unwanatham, Theerasuk Kawamatawong, Pennapa Jankum, Ammarin ThakkinstianAbstract:Background Persistent cough following an upper respiratory tract infection (URTI) is common in clinical practice. We investigated the effects of Procaterol on cough-specific quality of life (QoL) and peripheral-airway function among adults suffering from postinfectious cough (PIC). Methods This was a prospective, randomized, double-blinded placebo-controlled trial (NCT02349919) conducted at a university hospital. Seventy-four non-asthmatic adults who had persistent post-URTI cough for ≥3 weeks were assessed by a physical examination, chest/paranasal sinus radiographs, spirometry, and impulse oscillometry (IOS) and were allocated to receive Procaterol or placebo for 4 weeks. The Thai version of the Leicester Cough Questionnaire (LCQ-T), spirometry and IOS were assessed at baseline, 2 weeks, and 4 weeks. Results Mean LCQ-T total scores for the Procaterol group (10.8) and placebo group (10.9) at baseline were not significantly different (P=0.821). After adjustment for baseline Borg Cough Scale score and post-nasal drip, the mean between-group difference was not significant for LCQ-T total score (-1.26; 95% confidence interval [CI], -2.69 to 0.17), physical domain score (-0.35; 95% CI, -0.76 to 0.06), psychological domain score (-0.53; 95% CI, -1.06 to 0.01), or social domain score (-0.38; 95% CI, -0.92 to 0.16). Large improvements in LCQ-T total score were reported in both groups after 2 weeks (Procaterol, 4.21±2.73; placebo, 5.34±3.2), and 4 weeks (Procaterol, 5.94±3.68; placebo, 7.07±3.44). No differences between groups were found in the mean changes of spirometry or IOS parameters after 4 weeks. Conclusion Our study shows that Procaterol is not effective in the treatment of PIC, in terms of improvement of cough-specific QoL or peripheral-airway function.
Xin Zhou - One of the best experts on this subject based on the ideXlab platform.
-
efficacy of Procaterol combined with inhaled budesonide for treatment of cough variant asthma
Respirology, 2013Co-Authors: Wuping Bao, Qin Chen, Yanping Lin, Huiguo Liu, Guangdong Zhao, Zhibin Chen, Xin ZhouAbstract:Background and objective Procaterol, a selective, short-acting beta-2 adrenoceptor agonist, is effective in treating ‘classical’ asthma, but its efficacy for cough-variant asthma (CVA) is unknown. We evaluated the efficacy and safety of Procaterol combined with budesonide for CVA. Methods A prospective, randomized, double-blind, placebo-controlled, multicenter trial in China was conducted. One hundred and fifty-nine patients diagnosed with CVA (aged 18–75 years) were randomly divided into two groups to receive twice daily for 8 weeks, inhaled budesonide 100 μg plus either oral Procaterol 25 μg or placebo. Primary and secondary efficacy variables were cough symptom severity scores and Leicester Cough Questionnaire (LCQ) life quality scores. Adverse events were also assessed. Results The budesonide/placebo and budesonide/Procaterol groups contained 80 and 78 participants (one excluded for later diagnosis of eosinophilic bronchitis), respectively, with similar baseline characteristics. Daily cough score declined during treatment in both groups and was lower in the budesonide/Procaterol group at 8 (0.44 vs 0.73) and 10 (0.36 vs 0.69) weeks (P < 0.05). Compared with the budesonide/placebo group, the proportion of patients with a reduction of 3 points or greater (66% vs 42%) and that of patients scoring 0 points (63% vs 51%) was higher in the budesonide/Procaterol group for daily cough scores (P < 0.05). At 8 weeks, LCQ score improvement was superior in the budesonide/Procaterol group (38.94 ± 19.24 vs 32.71 ± 18.92; P < 0.05). Conclusion Procaterol combined with budesonide was well tolerated and effective at improving cough symptoms and quality of life in patients with CVA.
Kenneth R Chapman - One of the best experts on this subject based on the ideXlab platform.
-
changes in pulmonary function and cross sectional area of trachea and bronchi in asthmatics following inhalation of Procaterol hydrochloride and ipratropium bromide
The American review of respiratory disease, 1994Co-Authors: V Hoffstein, Noe Zamel, P A Mcclean, Kenneth R ChapmanAbstract:To determine the sites of action of inhaled adrenergic and anticholinergic bronchodilators, we used the acoustic reflection technique to measure airway area before and after administration of β 2 -selective adrenoreceptor agonist (Procaterol hydrochloride) and quaternary anticholinergic agent (ipratropium bromide). Eight stable individuals with asthma (five men and three women; mean age, 34±12.7 yr) were studied on 2 days in single-blind randomized crossover fashion when they self-administered (using metered-dose inhaler) two puffs of either Procaterol hydrochloride hemihydrate (10 μg/puff) or ipratropium bromide (20 μg/puff)
-
changes in pulmonary function and cross sectional area of trachea and bronchi in asthmatics following inhalation of Procaterol hydrochloride and ipratropium bromide
American Journal of Respiratory and Critical Care Medicine, 1994Co-Authors: V Hoffstein, Noe Zamel, P A Mcclean, Kenneth R ChapmanAbstract:To determine the sites of action of inhaled adrenergic and anticholinergic bronchodilators, we used the acoustic reflection technique to measure airway area before and after administration of beta 2-selective adrenoreceptor agonist (Procaterol hydrochloride) and quaternary anticholinergic agent (ipratropium bromide). Eight stable individuals with asthma (five men and three women; mean age, 34 +/- 12.7 yr) were studied on 2 days in single-blind randomized crossover fashion when they self-administered (using metered-dose inhaler) two puffs of either Procaterol hydrochloride hemihydrate (10 micrograms/puff) or ipratropium bromide (20 micrograms/puff). Maximal expiratory flow-volume curve, specific airway resistance, and cross-sectional areas of three airway segments (extrathoracic tracheal, intrathoracic tracheal, and bronchial) were recorded at baseline and 15, 30, 60, and 120 min after drug administration. Both agents produced significant improvements in FEV1, FVC and forced expiratory flow at 50% of vital capacity (V50), and specific airway resistance (SRaw) as early as 15 min after drug administration. These effects were sustained for the 120 min monitoring period. However, all improvements were significantly greater for Procaterol than for ipratropium. By contrast, there was no significant difference between drugs in the increased production in the cross-sectional areas of the three airway segments although there was a nonsignificant trend toward greater increases in tracheal area produced by the anticholinergic agent.(ABSTRACT TRUNCATED AT 250 WORDS)
Toshishige Inoue - One of the best experts on this subject based on the ideXlab platform.
-
aerosol characteristics of admixture of budesonide inhalation suspension with a beta2 agonist Procaterol
Allergology International, 2013Co-Authors: Toshiko Itazawa, Yuichi Adachi, Yasunori Ito, Osamu Higuchi, Hiroyuki Mochizuki, Naoki Shimojo, Toshishige InoueAbstract:ABSTRACT Background Nebulized drugs for asthma treatment are often mixed together in order to simplify inhalation regimens, although not recommended. We therefore evaluated aerosol characteristics and physicochemical stability of the admixture of an inhaled corticosteroid suspension with a beta2-agonist solution. Methods An 8-stage cascade impactor was used to measure the particle size distribution of admixture of Pulmicort ® Respules ® (budesonide, 0.5 mg/2 mL) with Meptin ® Inhalation Solution Unit (Procaterol hydrochloride, 30 Mg/0.3 mL) from a jet nebulizer, PARI LC Plus ® . Concentration of each drug was assayed with high- pressure liquid chromatography. Physicochemical compatibility was also assessed up to 24 hours after mixing. Results With regard to budesonide, impactor parameters such as mass median aerodynamic diameter (MMAD) and respirable mass (RM) were comparable between admixtures and single-drug preparations (2.92 ± 0.03 vs 2.99 ± 0.14 µm, 146.8 ± 2.9 vs 147.6 ± 8.2 µg, respectively). On the other hand, delivery rates of Procaterol increased when admixed with budesonide suspension, resulting in significantly higher RM (15.1 ± 0.8 vs 10.2 ± 0.5 µg, p Conclusions There is a possibility that admixture might influence of aerodynamic characteristics of Procaterol, but not budesonide. In vivo data will be needed for the clinical implications of our findings.